Tatva Chintan Pharma gains after Q2 PAT more than doubles to Rs 21 cr

Tatva Chintan Pharma Chem added 2.21% to Rs 1,945 after the company reported a 116.23% surge in consolidated net profit to Rs 21.45 crore in Q2 FY27, compared with Rs 9.91 crore in Q2 FY26.

Net sales jumped 75.94% year-on-year (YoY) to Rs 217.32 crore in the quarter ended 30 September 2026.

Profit before tax (PBT) soared 111.70% YoY to Rs 28.94 crore in Q2 FY27.

EBITDA surged 83% YoY to approximately Rs 40.7 crore in Q2 FY27, compared with Rs 22.2 crore in Q2 FY26. EBITDA margin improved to 19% from 18% in the corresponding quarter last year.

In terms of revenue contribution, Structure Directing Agents (SDA) accounted for 45% of total revenue, followed by Pharma & Agrochemical Intermediates (PASC) at 30%, Phase Transfer Catalysts (PTC) at 21%, Electrolyte Salts (ESS) at 3% and other products at 1%.

For the first half of FY27, the company reported a 125.93% rise in consolidated net profit to Rs 37.4 crore, compared with Rs 16.55 crore in H1 FY26. Revenue from operations increased 59.9% YoY to Rs 384.38 crore during the six-month period.

Tatva Chintan Pharma is an specialty chemicals manufacturer engaged in the production of specialty chemical products used in pharmaceuticals, agrochemicals, automotive applications and other industrial sectors. Its products cater to domestic and international customers, with applications spanning chemical synthesis, zeolite manufacturing, battery technologies and specialty industrial processes.

Powered by Capital Market - Live News